Published in Circulation on November 01, 1995
Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci U S A (2002) 3.59
A 50% reduction of excitability but not of intercellular coupling affects conduction velocity restitution and activation delay in the mouse heart. PLoS One (2011) 0.91
Sudden death is associated with a widened paced QRS complex in noncoronary cardiac disease. J Interv Card Electrophysiol (2006) 0.75
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 16.04
Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol (2002) 8.88
Cardiopulmonary resuscitation skills of preregistration house officers. Br Med J (Clin Res Ed) (1985) 8.45
Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ (1995) 6.28
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet (1999) 3.38
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J (1994) 3.13
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Chlamydia pneumoniae and coronary heart disease. BMJ (1997) 2.73
Colour Doppler flow mapping. BMJ (1990) 2.69
Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant (2011) 2.69
Major complications of coronary arteriography: the place of cardiac surgery. Br Heart J (1990) 2.61
Evaluation of the Directigen FluA+B test for rapid diagnosis of influenza virus type A and B infections. J Clin Microbiol (2002) 2.56
Left atrial appendage: structure, function, and role in thromboembolism. Heart (1999) 2.52
Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation (2001) 2.50
Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (1997) 2.50
Cost implications of the British Pacing and Electrophysiology Group's recommendations for pacing. BMJ (1992) 2.42
Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol (1991) 2.42
Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 2.31
Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart (2002) 2.23
The QT interval. Prog Cardiovasc Dis (2001) 2.22
Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol (1994) 2.21
Echocardiographic measurement of the normal adult right ventricle. Br Heart J (1986) 2.16
Atrial arrhythmias. Lancet (1993) 2.13
Effect of nifedipine on atrioventricular conduction as compared with verapamil. Intracardiac electrophysiological study. Br Heart J (1979) 2.06
Patient empowerment in secondary prevention of coronary heart disease. Lancet (2000) 2.03
The rhythm of the heart in active elderly subjects. Am Heart J (1980) 2.02
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf (2001) 2.02
Complete denervation of the heart in a child with congenital long QT and deafness. Am J Cardiol (1988) 2.00
Cardiac arrhythmia suppression trial and flecainide. Lancet (1989) 1.98
Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. Lancet (1989) 1.96
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
Components of heart rate variability--what they really mean and what we really measure. Am J Cardiol (1993) 1.91
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS (1989) 1.78
Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol (1992) 1.74
Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation (1998) 1.74
Effect of intravenous propranolol on QT interval. A new method of assessment. Br Heart J (1980) 1.71
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res (2000) 1.70
Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect (1995) 1.69
Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis (2000) 1.66
Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet (1988) 1.65
Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol (2000) 1.65
Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Br Heart J (1980) 1.64
Classification of atrial fibrillation. Pacing Clin Electrophysiol (1997) 1.63
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
A 500-kiloton airburst over Chelyabinsk and an enhanced hazard from small impactors. Nature (2013) 1.61
Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer (2004) 1.61
Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J (1989) 1.59
Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol (1992) 1.58
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis (2001) 1.57
Iatrogenic atrioventricular bypass tract following a Fontan operation for tricuspid atresia. Heart (1997) 1.55
The role of the high dependency unit in postoperative care: an update. Ann R Coll Surg Engl (1990) 1.54
Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation (1989) 1.53
Acute and chronic haemodynamic and electrophysiological effects of nifedipine in patients receiving atenolol. Br Heart J (1983) 1.52
Limitations of rate response of an activity-sensing rate-responsive pacemaker to different forms of activity. Pacing Clin Electrophysiol (1988) 1.51
Alterations in atrial electrophysiology associated with chronic atrial fibrillation in man. Eur Heart J (1999) 1.50
The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J (1984) 1.49
A clinical study of parenchymal and subdural miniature strain-gauge transducers for monitoring intracranial pressure. Neurosurgery (1996) 1.48
Isolation and mapping of a polymorphic DNA sequence (pEFD145) on chromosome 3 [D3S32]. Nucleic Acids Res (1988) 1.47
Catheter ablation for successful management of left posterior fascicular tachycardia: an approach guided by recording of fascicular potentials. Heart (1996) 1.47
Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants. Circulation (1992) 1.45
Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J (1998) 1.44
Atrial fibrillation begets trouble. Heart (1997) 1.43
Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics (1996) 1.43
Unrecognized dyslipoproteinemia in United Kingdom families recruited to a genetic register because of unexplained coronary heart disease. J Lab Clin Med (1994) 1.42
Ventricular tachycardia of left bundle branch block configuration in patients with isolated right ventricular dilatation. Clinical and electrophysiological features. Br Heart J (1984) 1.42
The impact of pancreas transplantation on kidney allograft survival. Am J Transplant (2011) 1.42
Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab (2014) 1.42
Do patients with neurally mediated syncope have augmented vagal tone? Am J Cardiol (1993) 1.41
Clinical anatomy of the atrioventricular junctions. J Am Coll Cardiol (1994) 1.41
Effect of magnesium sulphate in patients with unstable angina. A double blind, randomized, placebo-controlled study. Eur Heart J (1997) 1.41
Implantable cardioverter defibrillators and fitness to drive. Lancet (1994) 1.41
Influence of the infarct site on the identification of patients with ventricular tachycardia after myocardial infarction based on the time-domain and spectral turbulence analysis of the signal-averaged electrocardiogram. Clin Cardiol (1995) 1.41
Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J (1989) 1.40
Side effects and possible contraindications of amiodarone use. Am Heart J (1983) 1.40
The Percutaneous Cardiac Mapping and Ablation Registry: final summary of results. Pacing Clin Electrophysiol (1988) 1.39
Influence of posture and reference point on central venous pressure measurement. BMJ (1991) 1.39